AK3: A Potential Drug Target and Biomarker for Various Diseases

Target Name: AURKC

NCBI ID: G6795

AURKC

AK3: A Potential Drug Target and Biomarker for Various Diseases

Aurora-related kinase (AK) 3 (Aur3) is a protein that is expressed in various tissues and cells, including the brain, heart, and skeletal muscles. It is a key regulator of cell survival and proliferation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of AK3 is its role in the regulation of cell proliferation. In cancer cells, AK3 is activated when the cell has been treated with growth factors, such as insulin-like growth factor (IGF), and this activation promotes the growth and survival of the cancer cells. This is because AK3 plays a role in the regulation of several cell signaling pathways that are involved in cell proliferation, including the TGF-β pathway.

Another important function of AK3 is its role in the regulation of cell survival. In diseases such as neurodegenerative diseases, AK3 is often overexpressed, which can lead to the death of brain cells and the progressive loss of cognitive function. This is because overexpression of AK3 can cause the formation of neurofibrillary tangles, which are thought to contribute to the development of neurodegenerative diseases.

In addition to its role in cell proliferation and survival, AK3 is also involved in the regulation of cell adhesion. This is important for the development and maintenance of tissues and organs, and is also involved in the regulation of stem cell proliferation.

Given the importance of AK3 in the regulation of cell survival and proliferation, it is a potential drug target for a variety of diseases. For example, in neurodegenerative diseases, drugs that can inhibit the activity of AK3 may be effective in treating the disease. Similarly , in cancer, drugs that can inhibit the formation of neurofibrillary tangles and promote the regression of established cancer tumors may be effective in treating cancer.

In addition to its potential as a drug target, AK3 is also a potential biomarker for a variety of diseases. For example, the levels of AK3 have been elevated in the brains of individuals with Alzheimer's disease, and may be a potential diagnostic biomarker for this disease. Similarly, the levels of AK3 have been elevated in the urine and plasma of individuals with multiple sclerosis, and may be a potential diagnostic biomarker for this disease.

Overall, Aurora-related kinase 3 (Aur3) is a protein that is involved in a number of important cellular processes, including cell proliferation, survival, and adhesion. Its potential as a drug target and biomarker make it an attractive target for the development of new treatments for a variety of diseases.

Protein Name: Aurora Kinase C

Functions: Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Also plays a role in meiosis and more particularly in spermatogenesis. Has redundant cellular functions with AURKB and can rescue an AURKB knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin and INCENP leading to increased AURKC activity. Phosphorylates TACC1, another protein involved in cell division, at 'Ser-228'

The "AURKC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AURKC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets